IL7 and lymphopenia: IL-7 increased proliferative capabilities and induced sustained increases of PBMC counts when administered in “clustered” doses (143); finally, IL-7 treatment prevented lymphopenia associated with IFN-α treatment while stimulating CD8+ CTLs against SIV (144).